美德纳Moderna（MRNA）2025年第一季度财务业绩和业务更新报告「NASDAQ」（英文版）（9页）.pdf

1、 1 Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates Reports first quarter revenues of$0.1 billion,GAAP net loss of$(1.0)billion and GAAP EPS of$(2.52)Reiterates 2025 expected revenue range of$1.5 to$2.5 billion and 2025 year-end cash balance of approximately$6 billi

2、on Announces reduction of$1.4 to$1.7 billion in estimated GAAP operating costs by 2027 Advancing up to 10 products toward approval,including multiple oncology candidates CAMBRIDGE,MA/ACCESSWIRE/May 1,2025/Moderna,Inc.(NASDAQ:MRNA)today reported financial results and provided business updates for the

3、 first quarter of 2025.In the first quarter,we continued to execute with financial discipline,significantly reducing our operating expenses,and further prioritized our investments in oncology,said Stphane Bancel,Chief Executive Officer of Moderna.“Looking ahead,we are reiterating our 2025 financial

4、framework and announcing a cost structure that is expected to reduce our annual operating expenses by approximately$1.5 billion by 2027.With several Phase 3 readouts approaching and continued momentum toward 10 product approvals,we remain confident in Modernas long-term outlook.Recent progress inclu

5、des:Commercial Updates COVID-19:The Company reported$84 million in Spikevax sales in the first quarter of 2025,which includes$29 million of U.S.sales and$55 million of international sales.As previously reported,Moderna entered into a tender opportunity in January to compete for COVID vaccine busines

6、s in the EU.RSV:The Company reported$2 million in mRESVIA sales in the first quarter of 2025.Modernas RSV vaccine for adults aged 60 years and older has been recently approved in Australia,Switzerland,Taiwan and the UK.First Quarter 2025 Financial Results Revenue:Total revenue for the first quarter